Navigation Links
VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
Date:11/19/2009

BEDFORD, Mass., Nov. 19 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis. In addition, VisEn has launched a new near infrared label, VivoTag 800® to add an additional wavelength channel to its current line of VivoTag fluorochromes which are used to label specific ligands of interest in a wide variety of in vivo and in vitro imaging applications. Both of the new 800 nm agents are well suited for imaging quantification on the VisEn FMT 2500(TM) LX quantitative tomography imaging system, which also has expanded wavelength capabilities to enable simultaneous imaging of up to four agents and biologies of interest in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 30+ different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense®, IntegriSense(TM), AngioSense(TM), OsteoSense®, Annexin-Vivo(TM), MMPSense(TM), Cat B FAST(TM), Cat K FAST(TM) and ReninSense(TM) FAST. VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes for custom agent development, and its NanoSpark® labeling nanoparticles, all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging. All VisEn agents and labels, including the new OsteoSense® 800 and VivoTag® 800 agents, are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas. Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
4. TRACE Launches Compendium
5. Karmanos Cancer Institute Launches Company and Innovative Breast Imaging Tool
6. CareFusion Launches Knowledge Portal to Provide Actionable Information Across Product Platforms
7. Custom Spine Launches Pathway AVID and Regent ACP at NASS
8. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
9. Cardio Vascular Medical Device Launches Corporate Website
10. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
11. Deloitte Recap Launches New Solution for Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. ... Communications, Inc. ("WRB"), a health care service center ... WRB specializes in relationship management programs for ... WRB will join ... commercialization support services for manufacturers, biotech firms, and other ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine ... of a Policy Response”, -The Rory Staunton Foundation Calls on Health & Human Services, ... Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released on ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: ... serve earlier this month as a Guest Speaker and Contributor to a weeklong series ... and Common Purpose. , Walter Schindler and SAIL Capital ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... are educating patients on peri-implantitis in Las Vegas, NV, and the ... a custom gum disease consultation and leading care for peri-implantitis, with or without ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, are now ... practicing in Mt. Pleasant, SC, with or without a referral. A full mouth reconstruction ... missing teeth in Charleston, SC. Those who suffer from gum disease, misaligned ...
Breaking Medicine News(10 mins):